2nd Annual Conference on Neuroscience R&D Technologies
September, 29-30th 2016, London
Meet NeuroProof CEO Olaf Schröder at the 2nd Annual Conference on Neuroscience R&D Technologies conference and discuss the presentation and latest NeuroProof assays for functional phenotypic CNS drug discovery.
NeuroProof at Axiogenesis Meeting in Cologne
September 7-9th 2016
NeuroProof project manager Dr. Benjamin Bader presented the latest results on functional phenotypic modeling of neuro-degenerative diseases using human iPSC-derived neurons and their comparison to well-known primary cell cultures growing on micro-electrode arrays. The topics presented include effects of alpha-synuclein and botulinum toxin on hIPSC derived neuronal networks.
MEA meeting 2016
Reutlingen, June 28th - July 1st
ISSCR stem cell meeting
San Francisco, 22-26.6.2016
If you are attending the ISSCR meeting in San Francisco, come visit our two NeuroProof contributions: 1) The poster by Nagel et al. about functional evaluation of Axol's patient-derived iPSC neurons carrying a presinilin-1 mutation presented by Naomi Wessel-Carpenter and 2) the poster by Bader et al. about multi-parametrically characterizing the functional in vitro phenotype of Axiogensis' different "4U" neuron series with data on seizurogenic compounds and on our novel phenotypic readout used for phenotypic in vitro disease modeling (here Parkinson) which is presented by Elena Kfoury.
World Preclinical Congress
NeuroProof and Axiogenesis present a poster about " Monitoring and adapting the functional phenotypic of developing human iPSC-derived neuronal networks using multi-variate analysis of MEA data". Visit out poster and discuss the latest developments in multi-parametric data analysis for phenotypic screening of human iPSC-derived neurons.
Channelopathy Meeting 2016
Meet Alexandre Fouassier in Paris who presents some of our work on modulating neuronal receptors in human iPSC-derived neurons.
Ono Pharmaceuticals and NeuroProof at the 31st International Conference of Alzheimer's Disease International (ADI)
21-24 April 2016, Budapest
Ono Pharmaceuticals and NeuroProof co-presented novel functional in vitro results on the electrophysiological Characterization of GABA-A alpha5 negative allosteric modulators in hippocampal neurons and their efficacy to rescue amyloid beta-induced effects compared to standard of care and known pro-cognitive agents. See "Publications" for more information.
High Content & Phenotypic Screening 2016
Cambridge, UK. 10.05.2016
NeuroProof and Axiogenesis present newest results on how to "shift and rescue functional phenotypes for in vitro disease modeling – linking human iPSC-derived dopaminergic neurons with multi-parametric analysis of electrophysiological MEA data.” We show how the midbrain-like functional phenotype of human iPSC dopaminergic neurons is affected by Parkinson-related toxins and how this can be rescued in vitro. Looking forward to getting your comments and questions.
Meet NeuroProof at the 9th International Symposium on Neuroprotection and Neurorepair
Leipzig, Germany, 20-21.04.2016
NeuroProof presents newest results on phenotypic comparison of activity patterns from different mouse brain region-specific neuron cultures with those from different human iPSC-derived neuronal networks. We provide a functional tool to characterize hiPSC cultures to optimize the culture condition towards higher reproducibility, a higher functional network complexity and desired functional phenotypes. Visit our poster on Wednesday, April 20th and the talk by Benjamin Bader on Thursday April 21st. For more information visit: http://www.neurorepair-2016.de
International Conference "Stem Cells in Drug Discovery"
Cambridge, UK. 6.4.2016.
NeuroProof and Axiogenesis present a poster about "multi-parametric comparison of functional activities between mouse brain region-specific neuron cultures and human iPSC-derived neuronal networks grown on MEAs". We compared electrical functional activity patterns from primary murine neuronal cell cultures and hiPSC neuronal networks cultivated on MEA and show their uniqueness, reproducibility and functional similarity to relevant brain region-specific primary cultures.